ASCO 2022 Conference Coverage

 

Skin
10:27

ASCO 2022 Conference Coverage

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A Phase III Trial - ECOG-ACRIN EA6134

FEATURING Michael Atkins
  • 215 views
  • August 19, 2022
  • 1
01:37

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

FEATURING Adil Daud
  • 15 views
  • August 3, 2022
18:11

ASCO 2022 Conference Coverage

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

FEATURING Adil Daud
  • 270 views
  • August 3, 2022
14:22

ASCO 2022 Conference Coverage

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Unresectable Melanoma: OS and ORR by Key Subgroups From the RELATIVITY-047

FEATURING Evan Lipson
  • 336 views
  • July 14, 2022
  • 2
02:01

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating Triplet Combinations of IO and TT for BRAF V600m Unresectable/Metastatic Melanoma

FEATURING Pier Francesco Ferrucci
  • 11 views
  • July 7, 2022
09:28

ASCO 2022 Conference Coverage

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating Triplet Combinations of IO and TT for BRAF V600m Unresectable/Metastatic Melanoma

FEATURING Pier Francesco Ferrucci
  • 110 views
  • July 7, 2022
05:48

ASCO 2022 Conference Coverage

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma During Modern Therapy

FEATURING Kristina Orlova
  • 300 views
  • June 30, 2022
  • 2
04:30

ASCO 2022 Conference Coverage

ASCO 2022 on ARTISTRY-6 Trial: Nemvaleukin Alfa Monotherapy in Advanced Mucosal and Cutaneous Melanoma

FEATURING Jeffrey Weber
  • 118 views
  • June 27, 2022
50

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ARTISTRY-6 Trial: Nemvaleukin Alfa Monotherapy in Advanced Mucosal and Cutaneous Melanoma

FEATURING Jeffrey Weber
  • 20 views
  • June 27, 2022
27

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Long-Term Toxicities With Immune Checkpoint Inhibitor in Melanoma Patients

FEATURING Justin Tong
  • 321 views
  • June 21, 2022
  • 3
11:46

ASCO 2022 Conference Coverage

ASCO 2022 on Long-Term Toxicities With Immune Checkpoint Inhibitor in Melanoma Patients

FEATURING Justin Tong
  • 513 views
  • June 21, 2022
05:28

ASCO 2022 Conference Coverage

ASCO 2022 Primary Ipi/Nivo Followed by Adjuvant Nivo in Pts With Locally Advanced or Oligometastatic Melanoma

FEATURING Emilia Cocorocchio
  • 207 views
  • June 16, 2022
06:03

ASCO 2022 Conference Coverage

ASCO 2022 on Survival Update of Neoadjuvant Ipi + Nivo in Macroscopic Stage III Melanoma: The OpACIN and OpACIN-neo Trials

FEATURING Judith Versluis
  • 40 views
  • June 16, 2022
07:54

ASCO 2022 Conference Coverage

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in BRAF-Mutated Melanoma: A Subgroup Analysis With a Longer Follow-Up

FEATURING Paolo A. Ascierto
  • 110 views
  • June 16, 2022
01:23

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Thromboembolism and Association With Survival in Pts With Melanoma Receiving Chemo/IO

FEATURING Tamara Sussman
  • 13 views
  • June 15, 2022
08:48

ASCO 2022 Conference Coverage

ASCO 2022 on Thromboembolism and Association With Survival in Pts With Melanoma Receiving Chemo/IO

FEATURING Tamara Sussman
  • 110 views
  • June 15, 2022
16:53

ASCO 2022 Conference Coverage

ASCO 2022: Real-World Evaluation of the Association Between Baseline Metastatic Patterns and Clinical Outcomes Among BRAF+ Metastatic Melanoma Patients

FEATURING Zeynep Eroglu
  • 130 views
  • June 13, 2022
09:33

ASCO 2022 Conference Coverage

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy & Safety of Sequencing With Vemurafenib + Cobimetinib Followed by Atezo in Advanced BRAFV600+ Melanoma

FEATURING Elisabeth Livingstone
  • 124 views
  • June 13, 2022
  • 1
55

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Nivolumab + Relatlimab vs. Nivo in 1L Metastatic/Unresectable Melanoma: OS & ORR by Key Subgroups From the RELATIVITY-047

FEATURING Piotr Rutkowski
  • 18 views
  • June 9, 2022
05:06

ASCO 2022 Conference Coverage

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo in 1L Metastatic/Unresectable Melanoma: OS & ORR by Key Subgroups

FEATURING Piotr Rutkowski
  • 1,104 views
  • June 9, 2022
45

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated With Nivo + Ipi in CheckMate 067

FEATURING Piotr Rutkowski
  • 13 views
  • June 9, 2022
04:49

ASCO 2022 Conference Coverage

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated With Nivo + Ipi in CheckMate 067

FEATURING Piotr Rutkowski
  • 132 views
  • June 9, 2022
14:06

ASCO 2022 Conference Coverage

ASCO 2022 Analysis of the Effect of Systemic Corticosteroids on Survival From Tebentafusp in a Phase III Trial of Metastatic Uveal Melanoma

FEATURING Alexandra Ikeguchi
  • 58 views
  • June 8, 2022
  • 1